XIAO, Yuanyuan,BAIS, Carlos,CHOI, Younjeong,CONSALVO, Nicola, C.
申请号：
HK18102570.4
公开号：
HK1242996A
申请日:
2018.02.22
申请国别(地区):
HK
年份:
2018
代理人:
摘要：
The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.
